{"id":"W2513734563","doi":"10.1016/j.cllc.2016.07.007","title":"Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations","year":2016,"lang":"en","type":"article","venue":"Clinical Lung Cancer","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre; Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; Astellas Foundation for Research on Metabolic Disorders","keywords":"Erlotinib; Medicine; Epidermal growth factor receptor; Lung cancer; Internal medicine; Erlotinib Hydrochloride; Oncology; Placebo; Adverse effect; Pharmacology; Clinical endpoint; Cancer; Randomized controlled trial; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001534662,0.002336525,0.003565318,0.0006121682,0.0004680342,0.001317945,0.001236019,0.001947661,0.007073383],"category_scores_gemma":[0.001146597,0.001282675,0.002194495,0.00047625,0.001387349,0.001795847,0.00041373,0.00489622,0.001739953],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001027674,"about_ca_system_score_gemma":0.001548833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001474089,"about_ca_topic_score_gemma":0.00340107,"domain_scores_codex":[0.9995039,0.0002270924,0.00002107176,0.00009987747,0.00002994073,0.0001182057],"domain_scores_gemma":[0.9993877,0.0001161936,0.0001054987,0.00005991201,0.0000393353,0.0002913182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9438723,0.02472043,0.0006497575,0.0003313665,0.000644488,0.00006591935,0.00008602877,0.0008411682,0.008841164,0.0001744923,0.001774487,0.01799838],"study_design_scores_gemma":[0.8571525,0.1381243,0.001856538,0.00001457875,0.0003003078,0.00006268381,0.00003066375,0.0005458242,0.0008176953,0.00013237,0.0009382865,0.00002427056],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874213,0.002449978,0.000681916,0.000986932,0.0005609063,0.00275243,0.00180624,0.0002204551,0.003119921],"genre_scores_gemma":[0.9821146,0.002306196,0.001735775,0.001175907,0.0004767349,0.003619008,0.002805741,0.00006967556,0.005696391],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007073383,"threshold_uncertainty_score":0.02366281,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02682449255165086,"score_gpt":0.3907059977854347,"score_spread":0.3638815052337838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}